The anti-cytokine immunotherapy of type 2 diabetes is a new treatment method in recent years, especially blocking IL-1β in the process of impaired insulin secretion and insulin resistance, and can be used as a potential therapeutic target to reverse the quality and function of β cells [44–46]. This evidence concerns the gene INS and type 2 diabetes mellitus.